Evidence map›Paper›PMID 42208981›Full record

ArticleJournal for immunotherapy of cancer2026

CLEC2B-KLRB1 axis acts as an immune checkpoint, governing the exhaustion of CD8

Jie Cheng, Jiahua Lu, Zhaoya Gao, Yifeng Xiao, Pengju Chen, Mengting Zhou, Dandan Huang, Zihao Zhao, Xiaohui Zhang, Yuan Zhao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jie Cheng *Department of Pathology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, Hubei, China jiecheng2024@hust.edu.cn limingmd@126.com zlgujin@126.com.ORCID http://orcid.org/0009-0000-8125-2901
Jiahua Lu *Department of Pathology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Zhaoya Gao *Department of Gastrointestinal Surgery, Peking University Shougang Hospital, Beijing, China.
Yifeng Xiao *State Key Laboratory of Molecular Oncology, School of Life Sciences, Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing, China.
Pengju Chen *Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Unit III of Gastrointestinal Cancer Centre, Peking University Cancer Hospital and Institute, Haidian District Beijing, China.
Mengting ZhouDepartment of Pathology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Dandan HuangDepartment of Gastrointestinal Surgery, Peking University Shougang Hospital, Beijing, China.
Zihao ZhaoSchool of Life Sciences, Center for Statistical Science, Peking University, Beijing, China.ORCID http://orcid.org/0009-0009-5322-9451
Xiaohui ZhangState Key Laboratory of Natural and Biomimetic Drugs, Beijing, China.
Yuan ZhaoNational "111" Center for Cellular Regulation and Molecular Pharmaceutics (Ministry of Education), Hubei University of Technology, Wuhan, China.
Ming LiDepartment of Gastrointestinal Surgery, Peking University Shougang Hospital, Beijing, China jiecheng2024@hust.edu.cn limingmd@126.com zlgujin@126.com.
Jin GuDepartment of Gastrointestinal Surgery, Peking University Shougang Hospital, Beijing, China jiecheng2024@hust.edu.cn limingmd@126.com zlgujin@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany patients with cancer benefit little from immune checkpoint blockade (ICB), a major obstacle to immunotherapy for decades. Finding alternative immune checkpoints that control CD8

methodsSpatial proximity is essential for suppressive ligand-receptor signaling. Here, we mapped the spatial tumor microenvironment of patients with MSS CRC at single-cell resolution and analyzed the cells interacting with exhausted CD8

resultsWe found that a subset of MSS CRC exhibits substantial CD8

conclusionsOur study revealed CLEC2B-KLRB1 as a previously unrecognized immune checkpoint axis that drives T-cell exhaustion specifically in ICB poor responsive MSS CRC. Blockade of KLRB1 with a therapeutic antibody reinvigorated CD8

Indexed as

CD8-Positive T-LymphocytesColorectal NeoplasmsImmune Checkpoint InhibitorsLectins, C-TypeReceptors, ImmunologicAnimalsDrug Resistance, NeoplasmHumansMiceT-Cell ExhaustionTumor MicroenvironmentImmune Checkpoint InhibitorsLectins, C-TypeReceptors, ImmunologicColorectal CancerImmune Checkpoint InhibitorT cell

Identifiers

PMID42208981
PMCPMC13223962

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.